Less than four months after securing a broad license from Roche Molecular Systems Inc. (a division of Roche ) to use PCR for clinical diagnostics, PE Corp. has hired Roche Molecular's CEO, Kathy Ordonez, to build a new division within PE that will draw on the technology resident in PE's Applied Biosystems Group (ABI) and Celera Genomics Group units to develop, seek approval for, and market reagent and software-based standardized molecular diagnostic tests that will run on ABI's instruments.
ABI has been in the diagnostics business on a small scale via the development of a system for HIV genotyping that is now marketed to the research community and for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?